CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
CANADA

About Us

Conference

Partner With Us

  • APAC
    • US
    • EUROPE
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    Bioinformatics & Genomics
    BioTech
    Cell and Gene Therapy
    Drug Discovery and Development
    Life Science AI
    Next-Generation Sequencing
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    CDMO
    Cosmetic
    CRO
    Life Science Testing And Compliance
    Supplement Manufacturing
  • Business Services
    Life Science Consulting
    Life Sciences Marketing and Communication
    Peptide
  • Leadership Perspectives
  • Innovation Insights
  • News
  • Magazines
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

Clinical Trial Management Moves Toward A More Connected Model

A clinical trial can look straightforward on paper. 

By

Life Sciences Review | Tuesday, August 25, 2026

A clinical trial can look straightforward on paper. There is a protocol to follow, a group of participants to recruit and a series of visits, assessments and reports to complete. In practice, keeping all those pieces moving at the same pace is considerably harder. Sites operate in different locations, patients have different needs and even a small delay can affect timelines further down the line.


That complexity is particularly visible across the Asia-Pacific region. The market includes countries with different healthcare systems, regulations, languages and research capabilities. Sponsors running trials across several countries have to manage those differences while maintaining consistent standards for data quality, patient safety and study conduct.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.


Clinical trial management has therefore become as much about coordination as it is about technology. Sponsors, contract research organizations, investigators, clinical teams and patients all contribute to the progress of a study. When information moves slowly between them, problems can remain hidden until they become difficult to fix.


The focus is shifting towards giving research teams a clearer view of what is happening across a trial while keeping the work manageable for the people responsible for it.


Keeping Complex Studies on Track


The day-to-day work behind a clinical trial involves a long list of details. Sites need to be activated, participants recruited, visits scheduled, data reviewed and documentation maintained. Each task depends on others being completed correctly and on time.


Digital trial management systems are helping bring these activities together. Teams can monitor site performance, track milestones, review study documents and follow recruitment progress without relying on disconnected spreadsheets and email threads.


“Clinical trial management has therefore become as much about coordination as it is about technology.”


That visibility matters when a trial involves dozens of sites. A recruitment slowdown at one location may be easy to overlook when information is scattered across different systems. A connected view gives study teams an opportunity to investigate the problem earlier, understand what is happening and decide whether additional support is needed.


Data Is Becoming Easier to Follow


Clinical trials generate enormous amounts of information, from patient assessments and laboratory results to site records and safety reports. Managing that information accurately is essential because decisions made during a trial depend on the quality of the data available.


Electronic data capture has become an important part of this process, allowing research teams to collect and review information digitally rather than relying heavily on paper records. Automatic checks can identify missing entries and inconsistencies in data, enabling sites to make corrections and providing them the time to resolve them.


Remote monitoring and digital communication have added another layer of flexibility. Study teams can review certain information without always needing to be physically present at a site, which can be particularly useful when trials span large geographic areas.


Artificial intelligence is beginning to support some of these activities. It can help organize information, identify unusual patterns and assist teams in reviewing large volumes of records. Its usefulness, however, depends on the quality of the underlying data and the judgement of the people reviewing the results.


The Patient Experience Matters More Than Ever


A well-managed trial is not measured only by whether a sponsor meets its timeline. Patients are giving their time, undergoing procedures and often rearranging work or family commitments to take part. If participation becomes unnecessarily difficult, recruitment and retention can suffer.


That has encouraged research teams to pay closer attention to the patient experience. Digital appointment reminders, remote visits where appropriate and simpler communication can reduce some of the practical burdens associated with participation.


The approach has to work for the study and the people involved. Some patients may have limited access to technology, while certain assessments still need to be done in person. A digital-first model is most effective when it takes into account how patients and research sites actually work.


Patient communication is another area where small improvements can have a real effect. Clear instructions, timely updates and easy ways to ask questions can help participants feel informed throughout the study rather than left wondering what happens next.


Managing Trials Across Borders


Asia-Pacific offers significant opportunities for clinical research, but its diversity creates challenges that cannot be solved through technology alone. Sponsors may have to work across different regulatory frameworks, healthcare environments and cultural expectations while maintaining a consistent study protocol.


Local expertise still matters. Research teams that know the requirements and day-to-day realities of each market can help sponsors avoid unnecessary delays while building stronger relationships with investigators and participants.


Regulatory submissions, site management and documentation also require careful coordination. A process that works well in one country may need adjustment elsewhere. Successful trial management depends on knowing where consistency is essential and where local adaptation makes sense.


The most effective technology supports that work without adding another layer of complexity. Systems need to be intuitive enough for busy site teams to use and flexible enough to accommodate differences between markets.


Clinical trial management will continue to evolve as new therapies, decentralized approaches and digital research tools change how studies are conducted. Yet the fundamentals remain familiar. Trials still depend on people who can coordinate effectively, identify problems early and keep participants at the center of the work.


Technology can provide a clearer picture of a study and reduce some of the administrative burden, but it cannot replace clinical judgement or strong relationships between sponsors, investigators and patients. Across APAC, where clinical research increasingly crosses borders and involves diverse populations, that balance will be crucial. The strongest trial management approaches will be those that make complex studies easier to manage without losing sight of the people who make the research possible.


More in News

Growing Concerns About Data Continuity in Biopharma Evidence Generation

One of the common concerns within biopharma is not a matter of generating evidence per se. What makes it even harder is the possibility of sustaining a consistent stream of information through several studies or regulations over prolonged periods of time. As such, the issue of data continuity gains more importance as evidence generation software solutions are currently evaluated by potential buyers. Evidentiary initiatives are never limited to the sole scope of their objectives. Information retrieved once can become relevant several times over the life cycle of a particular product. Researchers may need to re-examine certain findings, compare results of treatment between different periods of time or study data acquired within separate research processes. It becomes especially complicated if there are no consistent information sources within an organization. Such considerations begin to impact the choice of evidence generation software. While the tools themselves are hardly ever used to produce any scientific insights directly, their contribution lies in facilitating further evidence processing and management. The problem becomes apparent as evidentiary research programs move past their initial objectives. It is rare for evidence generation initiatives to have a definite deadline or goal. Several years may pass between the start of the research process and its end, which means that there can be many staff changes, reconsiderations of previous assumptions or emergence of new questions. When information proves hard to find or analyze, the whole process can be slowed down significantly. The amount of effort spent tracking documents, verifying the integrity of information and understanding research history may prove to be considerable. At the same time, these aspects might not become a major focus of technology evaluation. Procurement conversations about evidence generation software solutions are shifting in this direction. Buyers' attention moves from operational effectiveness to information sustainability as evidence programs grow more extensive and complex. They are starting to see evidence generation software platforms as tools for sustaining knowledge over time rather than project management resources. This brings a change to the list of priorities for software developers. Features aimed at optimizing research processes are essential but buyers become concerned with data preservation as well. As such, information continuity becomes part of a solution's institutional memory function rather than just another aspect of project management. While data continuity may not be as prominent as some new trends in evidence analytics, it addresses a pressing problem faced by many biopharma teams. Evidence generation projects tend to outlast their budgets, original objectives or even the members of a team conducting research. For biopharma companies investing in such tools, the problem is shifting from acquiring new information to keeping existing data context-sensitive. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

Autologous and Allogeneic Models Push Cell Therapy Toward Different Development Paths

Cell therapy product development is becoming more segmented as autologous and allogeneic products place different demands on design, manufacturing and commercialization. Developers can no longer discuss the sector as one uniform category. Product strategy depends heavily on whether cells come from the patient or from a donor source. Autologous therapies are often built around individualized production. A patient’s own cells are collected, processed and returned as a therapy. This model can create a strong biological fit, but it also places pressure on scheduling, chain of identity, release timelines and site coordination. Every patient-specific batch becomes both a treatment and a manufacturing event. Allogeneic therapies take a different approach. Instead of using each patient's own cells, they rely on donor-derived or engineered cells that can be produced in larger batches and supplied to more patients. This model has the potential to improve access and make therapies more widely available, provided quality, immune compatibility and long-term performance are carefully managed. At the same time, it brings its own set of challenges, including how cells are sourced, how consistently they can be expanded during manufacturing, how they are stored and how different patients may respond to the treatment. Industry analysis from Thermo Fisher Scientific’s Patheon unit notes that autologous therapies require individualized handling because each treatment is tailored to a patient’s cells, while allogeneic therapies must ensure consistent quality and address immune compatibility across recipients. These differences influence product development from the very beginning. For autologous therapies, developers often concentrate on coordinating the entire vein-to-vein process, including logistics, site readiness, rapid release testing and making sure each patient's cells move through the system efficiently. Developers of allogeneic therapies face a different set of priorities, with greater attention on master cell banks, consistency between production batches, inventory management and large-scale quality control. Each approach comes with its own operational challenges, costs and risks that need to be managed throughout development. Manufacturing partners are therefore becoming more specialized. A partner supporting allogeneic production may need scale-up expertise and robust batch release processes. Developers must choose partners based on model fit, not general cell therapy experience alone. Digital systems are becoming important in both pathways. Developers need data continuity from cell collection through manufacturing and administration. Gaps in records can create delays and weaken confidence. Better data handling can support quality review and long-term learning across batches or patient cases. The future of cell therapy product development will likely involve both models advancing in parallel. Autologous and allogeneic approaches solve different problems and face different barriers. The companies best positioned will be those that align biology, manufacturing design, clinical planning and commercial delivery around the specific therapy model they are building. ...Read more
Life Sciences Review APAC
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review APAC. All rights reserved.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreviewapac.com/news/clinical-trial-management-moves-toward-a-more-connected-model-nwid-3691.html